S. H. Swerdlow, E. Campo, N. L. Harris, E. S. Jaffe, S. A. Pileri, H. Stein, J. Thiele and J. W. Vardiman, “WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues,” International Agency for Research on Cancer (IARC), Lyon, 2008.
 R. Soutar, H. Lucraft, G. Jackson, et al., “Guidelines on the Diagnosis and Management of Solitary Plasmacytoma of Bone and Solitary Extramedullary Plasmacytoma,” British Journal of Haematology, Vol. 124, No. 6, 2004, pp. 717-726.
 Annon, “Criteria for the Classification of Monoclonal Gammopathies, Multiple Myeloma and Related Disorders: A Report of the International Myeloma Working Group,” British Journal of Haematology, Vol. 121, No. 5, 2003, pp. 749-757.
 M. S. Linet, S. D. Harlow and J. K. McLaughlin, “A Case-Control Study of Multiple Myeloma in Whites; Chronic Antigenic Stimulation, Occupation and Drug Use,” Cancer Research, Vol. 47, No. 11, 1987, pp. 2978-2981.
 R. A. Kyle, M. A. Gertz, T. E. Witzig, J. A. Lust, M. Q. Lacy, A. Dispenzieri, R. Fonseca, et al., “Review of 1027 Patients with Newly Diagnosed Multiple Myeloma,” Mayo Clinic Proceedings, Vol. 78, No. 1, 2003, pp. 21-33.
 E. E. C. Ceballos, J. E. C. Franco, J. R. E. Zamora and J. R. L. Méndez, “Oncologists Clinical of Iberoamerica. Hemato-Oncology. Part I,” Planeation and Development Editorial, S.A. of C.V., 2009, pp. 82-84.
 P. Lin, R. Owens, G. Tricot and C. S. Wilson, “Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple Myeloma,” American Journal of Clinical Pathology, Vol. 121, No. 4, 2004, pp. 482-488.
 N. Sahara, A. Takeshita, K. Shigeno, S. Fujisawa, K. Takeshita, et al., “Clinicopathological and Prognostic Characteristics of CD56 Negative Multiple Myeloma,” British Journal of Hematology, Vol. 117, No. 4, 2002, pp. 882-885.
 R. K?nigsberg, N. Zojer, J. Ackerman, E. Kr?mer, H. Kittler, E. Fritz, et al., “Predictive Role of Interphase Cytogenetics for Survival of Patients with Multiple Myeloma,” Journal of Clinical Oncology, Vol. 18, No. 4, 2000, pp. 804-812.
 R. Fonseca, E. A. Blood, M. M. Oken, R. A. Kyle, G. W. Dewald, R. J. Bailey et al., “Myeloma and the t(11; 14) (q13; q32); Evidence for a Biologically Defined Unique Subset of Patients,” Blood, Vol. 99, No. 10, 2002, pp. 3735-3741.
 J. D. Hoyer, C. A. Hanson, R. Fonseca, P. R. Greipp, G. Dewald and P. J. Kurtin, “The (11; 14) (q13; q32) Translocation in Multiple Myeloma,” American Journal of Clinical Pathology, Vol. 113, No. 6, 2000, pp. 831-837.
 H. Chang, S. Samiee and Q. L. Yi, “Prognostic Relevance of CD56 Expression in Multiple Myeloma: A Study Including 107 Cases Treated with High-Dose Melphalan-Based Chemotherapy and Autologous Stem Cell Transplant,” Leukemia & Lymphoma, Vol. 47, No. 1, 2006, pp. 43-47. doi:10.1080/10428190500272549